STOCK TITAN

Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences clinical trial

Cellectar Biosciences (NASDAQ: CLRB) announced that new data from their Phase 2 CLOVER-WaM study of iopofosine I 131 for Waldenstrom's macroglobulinemia (WM) treatment will be presented at ASH 2024. The study focuses on relapsed and refractory WM patients who received at least 2 prior therapies. The company plans to submit a New Drug Application to the FDA in the coming months and will seek priority review. Dr. Sikander Ailawadhi from Mayo Clinic will present the efficacy and safety results during an oral session on December 9, 2024, at the Marriott Marquis San Diego Marina.

Cellectar Biosciences (NASDAQ: CLRB) ha annunciato che nuovi dati del loro studio di Fase 2 CLOVER-WaM sull'iopofosina I 131 per il trattamento della macroglobulinemia di Waldenstrom (WM) saranno presentati all'ASH 2024. Lo studio si concentra su pazienti con WM recidivante e refrattaria che hanno ricevuto almeno 2 terapie precedenti. L'azienda prevede di presentare una Nuova Domanda di Farmaco all'FDA nei prossimi mesi e cercherà una revisione prioritaria. Il Dr. Sikander Ailawadhi della Mayo Clinic presenterà i risultati di efficacia e sicurezza durante una sessione orale il 9 dicembre 2024, presso il Marriott Marquis San Diego Marina.

Cellectar Biosciences (NASDAQ: CLRB) anunció que se presentarán nuevos datos de su estudio de Fase 2 CLOVER-WaM sobre iopofosina I 131 para el tratamiento de la macroglobulinemia de Waldenstrom (WM) en ASH 2024. El estudio se centra en pacientes con WM en recaída y refractaria que han recibido al menos 2 tratamientos previos. La compañía planea presentar una Nueva Solicitud de Medicamento a la FDA en los próximos meses y solicitará una revisión prioritaria. El Dr. Sikander Ailawadhi de la Mayo Clinic presentará los resultados de eficacia y seguridad durante una sesión oral el 9 de diciembre de 2024, en el Marriott Marquis San Diego Marina.

Cellectar Biosciences (NASDAQ: CLRB)Waldenstrom의 점액구성 단백질 증가증(WM) 치료를 위한 iopofosine I 131의 2상 CLOVER-WaM 연구 데이터가 ASH 2024에서 발표될 예정이라고 발표했습니다. 이 연구는 최소 2회의 이전 치료를 받은 재발성 및 난치성 WM 환자에 중점을 두고 있습니다. 회사는 향후 몇 달 안에 FDA에 신약 신청서를 제출할 예정이며, 우선 심사를 요청할 것입니다. Mayo Clinic의 Sikander Ailawadhi 박사가 2024년 12월 9일 Marriott Marquis San Diego Marina에서 진행되는 구두 발표 세션에서 효능 및 안전성 결과를 발표할 예정입니다.

Cellectar Biosciences (NASDAQ: CLRB) a annoncé que de nouvelles données de leur étude de Phase 2 CLOVER-WaM sur l'iopofosine I 131 pour le traitement de la macroglobulinémie de Waldenström (WM) seront présentées lors de l'ASH 2024. L'étude se concentre sur des patients atteints de WM en rechute et réfractaire qui ont reçu au moins 2 traitements antérieurs. La société prévoit de soumettre une Demande de Nouveau Médicament à la FDA dans les mois à venir et cherchera une révision prioritaire. Le Dr. Sikander Ailawadhi de la Mayo Clinic présentera les résultats d'efficacité et de sécurité lors d'une session orale le 9 décembre 2024, au Marriott Marquis San Diego Marina.

Cellectar Biosciences (NASDAQ: CLRB) gab bekannt, dass neue Daten aus ihrer Phase-2-Studie CLOVER-WaM zu iopofosine I 131 für die Behandlung von Waldenström-Makroglobulinämie (WM) auf der ASH 2024 präsentiert werden. Die Studie konzentriert sich auf Patienten mit WM, die eine Rückfall- oder Resistenzausbildung erfahren haben und zuvor mindestens 2 Therapien erhalten hatten. Das Unternehmen plant, in den kommenden Monaten einen Antrag auf Zulassung eines neuen Medikaments bei der FDA einzureichen und wird eine Prioritätsprüfung anstreben. Dr. Sikander Ailawadhi von der Mayo Clinic wird die Ergebnisse zur Wirksamkeit und Sicherheit während einer mündlichen Sitzung am 9. Dezember 2024 im Marriott Marquis San Diego Marina präsentieren.

Positive
  • Selected for oral presentation at major industry conference (ASH 2024)
  • Plans to submit New Drug Application to FDA in coming months
  • Seeking priority review status for drug approval
  • Potential first-in-class novel cancer targeting agent
Negative
  • Drug not yet approved in any country for any indication
  • Currently in late-stage clinical phase without guaranteed approval

Insights

This announcement about presenting Phase 2 trial data at ASH 2024 is a routine conference presentation update and does not include actual trial results or meaningful new data. While Cellectar's iopofosine I 131 shows promise for Waldenstrom's macroglobulinemia treatment and the company plans to submit an NDA in the coming months, this specific news about a future conference presentation does not provide actionable information for investors.

The selection for an oral presentation, while prestigious, is a standard academic achievement that doesn't materially impact the company's valuation or market position. Investors should wait for the actual presentation in December 2024 for meaningful data that could impact investment decisions.

Ailawadhi, Sikander, M.D., Lead Investigator, to Present Iopofosine I 131 Efficacy and Safety Results from Phase 2 CLOVER-WaM Study

Highlights Company’s Leadership and Progress in Developing Iopofosine I 131 as Treatment for Waldenstrom’s Macroglobulinemia

FLORHAM PARK, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that new data from the company’s open-label Phase 2 CLOVER-WaM study of iopofosine I 131 as a potential treatment for Waldenstrom’s macroglobulinemia (WM) will be highlighted in an oral presentation at the 66th American Society of Hematology Annual Meeting and Exposition (ASH 2024) taking place from December 7–10, 2024, in San Diego, California.

Cellectar’s lead product candidate, iopofosine I 131, is a potential first-in-class, novel cancer targeting agent utilizing a phospholipid ether as a radioconjugate. Iopofosine I 131 is an investigational agent and has not been approved for use in any country, for any indication.

WM is the dominant subtype lymphoplasmacytic lymphoma that remains incurable with available therapies. Treatment options beyond initial therapy are limited, underscoring the need for new therapies with novel mechanisms of action.

The pivotal CLOVER-WaM (NCT02952508) trial assessed the efficacy and safety of iopofosine I 131 in relapsed and refractory patients with WM who received at least 2 prior therapies. 

“We are honored to have the positive results from our CLOVER-WaM pivotal trial selected for oral presentation at ASH 2024. This highlights the need for novel class therapies for an often-overlooked patient population affected by this rare disease in which iopofosine I 131 has the potential to establish itself as the standard-of-care for relapsed/refractory patients,” said James Caruso, president and CEO of Cellectar. “As previously announced, we plan to submit a New Drug Application with the U.S. Food and Drug Administration in the coming months and, given the limited effective therapeutic alternatives available for WM patients, will be seeking priority review.”

Details for the presentations are as follows:

Presenter: Ailawadhi, Sikander, M.D., professor of medicine, Division of Hematology/Oncology, Departments of Medicine and Cancer Biology, Mayo Clinic
Title: Iopofosine I 131 in Previously Treated Patients with Waldenstrom Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM™)
Session: Oral
Session Date: Monday, December 9, 2024 
Session Time: 2:45 PM – 4:15 PM
Location: Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13
Publication Number: 861

The complete abstract of the oral presentation can be accessed at the ASH 2024 website at 66th ASH Annual Meeting & Exposition - Hematology.org.

In-person participants at ASH 2024 may visit Cellectar Biosciences at Exhibit Booth #3300 in the Exhibit Hall (Halls B2-F at the San Diego Convention Center).

About Waldenstrom’s Macroglobulinemia

Waldenstrom’s Macroglobulinemia (WM) is a B-cell malignancy characterized by bone marrow infiltration with clonal lymphoplasmacytic cells that produce a monoclonal immunoglobulin M (IgM) that remains incurable with available treatments. The prevalence in the US is approximately 26,000 with 1,500–1,900 patients being diagnosed annually. Approximately 11,500 patients require treatment in the relapsed or refractory setting and there are an estimated 4,700 patients requiring third line or greater therapy. There are also approximately 1,000 patients that have exhausted all current treatment options by third line because they are ineligible or intolerant to those existing therapies. Therefore, the total addressable market for third line or greater therapy is approximately 5,700 patients. There are no U.S. Food and Drug Administration (FDA) approved treatment options for patients progressing on BTKi therapy. BTKi therapies do not demonstrate complete response rates and require continuous treatment.

Non-FDA approved treatments are used in more than 60% of patients. Over 50% of patients are treated with the same or similar treatment from prior lines of therapy. There is an established unmet need for new FDA-approved treatment like Iopofosine I-131 that provide a novel mechanism of action, increased deep durable responses, and time limited treatment, especially in heavily pretreated WM patients.

About Cellectar Biosciences, Inc.

Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC™) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.

The company’s product pipeline includes lead asset, iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Additional radiotherapeutics are in development utilizing alpha emitters and Auger to target solid tumors.

For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.

Forward-Looking Statement Disclaimer

This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes including our expectations regarding the CLOVER-WaM pivotal trial. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of iopofosine, the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability to maintain orphan drug designation in the United States for iopofosine, the volatile market for priority review vouchers, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K/A for the year ended December 31, 2023, and our Form 10-Q for the quarter ended June 30, 2024. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

Contacts

MEDIA:
Christy Maginn
Bliss Bio Health
703-297-7194
cmaginn@blissbiohealth.com

INVESTORS:
Anne Marie Fields
Precision AQ (formerly Stern IR)
annemariefields@precisionaq.com


FAQ

What is the purpose of Cellectar's Phase 2 CLOVER-WaM study for CLRB stock?

The study assesses the efficacy and safety of iopofosine I 131 in treating relapsed and refractory Waldenstrom's macroglobulinemia patients who received at least 2 prior therapies.

When will Cellectar (CLRB) present their CLOVER-WaM study results?

The results will be presented on December 9, 2024, during an oral session at the ASH 2024 conference in San Diego, California.

What are Cellectar's (CLRB) next steps for iopofosine I 131?

Cellectar plans to submit a New Drug Application to the FDA in the coming months and will seek priority review for iopofosine I 131.

Cellectar Biosciences INC NEW

NASDAQ:CLRB

CLRB Rankings

CLRB Latest News

CLRB Stock Data

64.17M
37.70M
2.84%
34.55%
4.52%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
FLORHAM PARK